Related Experiment Videos
[Sentinel lymph node procedure in thyroid carcinoma patients. Our experience].
M R Pelizzo1, I Merante Boschin, A Piotto
1Dipartimento di Patologia Speciale Chirurgica, Università di Padova, Padova, Italy.
Minerva Chirurgica
|March 29, 2006
Summary
Sentinel lymph node (SLN) mapping using vital blue dye in papillary thyroid carcinoma (PTC) is feasible but has limitations. The technique identified SLNs in 67.3% of patients, aiding nodal dissection, though dye-related complications were noted.
Area of Science:
- Oncology
- Surgical Pathology
- Nuclear Medicine
Context:
- Papillary thyroid carcinoma (PTC) surgical extent remains debated.
- Intraoperative lymphatic mapping aids nodal status assessment in other cancers.
- Sentinel lymph node (SLN) biopsy is a technique to identify the first lymph node(s) draining a tumor.
Purpose:
- To evaluate the feasibility of SLN mapping in PTC using intratumoral vital blue dye injection.
- To assess the utility of SLN biopsy in guiding nodal dissection for PTC.
- To determine the accuracy and limitations of blue dye-based SLN identification in PTC.
Summary:
- 110 PTC patients without clinical nodal involvement underwent SLN mapping via intratumoral blue dye injection.
- SLNs were identified in 67.3% of cases, with 31.1% positive for micro-metastases.
- Blue dye uptake by parathyroid glands and lymphatic disruption were observed complications.
Impact:
- SLN mapping can identify metastatic lymph nodes in PTC, potentially refining surgical dissection.
- The study highlights the need for improved SLN mapping techniques to overcome limitations like dye spread and identification failures.
- Accurate SLN identification is crucial for precise staging and tailored treatment of papillary thyroid carcinoma.